The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Sagar Lonial
Rakesh Popat
Rahul BanerjeeThe treatment landscape for multiple myeloma (MM) is rapidly evolving, and navigating options for patients with early relapsed/refractory MM has become increasingly complex.
The Multiple Myeloma Hub spoke with Rahul Banerjee, Sagar Lonial, and Rakesh Popat to gain their expert perspectives on current standards of care, the expanding role of targeted therapies, and key considerations for integrating novel agents into clinical practice.
Chapter 1 | What are the current treatment recommendations and unmet needs in early RRMM?
Chapter 2 | What is the rationale for treating early RRRM with targeted therapies?
Chapter 3 | How to incorporate novel therapies into the treatment paradigm for early RRMM?
More from this series:
.webp&w=3840&q=75)
